Dendritic cell-based immunotherapy for malignant glioma

Neuroscience Bulletin

Volumn 24, Issue 1, 2008, Pages 39-44

  Gu, Jin Hai ^a   Li, Gang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Dendritic cell; Immunotherapy; Malignant glioma

Indexed keywords

DENDRITIC CELL VACCINE; TUMOR ANTIGEN;

ABSENCE OF SIDE EFFECTS; BLOOD BRAIN BARRIER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LYMPHOID TISSUE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SHORT SURVEY; VACCINATION; DENDRITIC CELL; GLIOMA; IMMUNOLOGY; IMMUNOTHERAPY;

DENDRITIC CELLS; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 46149083969     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-008-1107-1     Document Type: Short Survey

References (38)

1. Cartmell T, Southgate T, Rees GS, Castro MG, Lowenstein PR, Luheshi GN. Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. J Neurosci 1999, 19: 1517-1523.
2. Harling-Berg CJ, Park TJ, Knopf PM. Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol 1999, 101: 111-127.
3. Perry VH. A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol 1998, 90: 113-121.
4. Stevenson PG, Freeman S, Bangham CR, Hawke S. Virus dissemination through the brain parenchyma without immunologic control. J Immunol 1997, 159: 1876-1884.
5. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Nat Acad Sci USA 2000, 97: 7482-7487.
6. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003, 3: 569-581.
7. Perry VH, Andersson PB. The inflammatory response in the CNS. Neuropathol Appl Neurobiol 1992, 18: 454-459.
8. Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol 2002, 23: 23-30.
9. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000, 21: 141-147.
10. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392: 245-252.
11. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999, 100: 216-232.
12. Zuber P, Kuppner MC, De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 1988, 18: 1623-1626.
13. Pollack IF, Okada H, Chambers WH. Exploitation of immune mechanisms in the treatment of central nervous system cancer. Semin Pediatr Neurol 2000, 7: 131-143.
14. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993, 25: 338-343.
15. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999, 90: 1115-1124.
16. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001, 61: 842-847.
17. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000, 103: 16-25.
18. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos K. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semiliki Forest virus-mediated complementary DNA. J Neurosurg 2001, 94: 474-481.
19. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 2001, 24: 106-113.
20. Ni H, Spellman SR, Jean WC, Hall WA, Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001, 51: 1-9.
21. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, et al. Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Neurosurg Focus 2000, 9: e8.
22. Siesjö P, Visse E, Sjogren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-γ treatment. J Immunother Emphasis Tumor Immunol 1996, 19: 334-345.
23. + progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocytederived dendritic cells. J Immunother 2000, 23: 48-58.
24. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999, 162: 168-175.
25. Schreurs MW, Eggert AA, Punt CJ, Figdor CG, Adema GJ. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Crit Rev Oncog 2000, 11: 1-17.
26. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999, 223: 1-15.
27. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001, 98: 8809-8814.
28. Yu JS, Wheeler CJ, Zeltzer PM. Dendritic cell immunotherapy for patients with glioblastoma multiforme and anaplastic astrocytoma. Proc Am Assoc Cancer Res 2001, 42: 1478. (Abstract)
29. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000, 11: 797-806.
30. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001, 22: 102-107.
31. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997, 150: 2143-2152.
32. Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M, et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 2000, 23: 511-518.
33. Liu FS, Wang ZC, Li JH, Lin S, Ren M, Xiao Q, et al. Experimental study of bone-marrow-derived dendritic cells pulsed with tumor antigens in the treatment for intracranial gliomas. Chin J Neurosurg 2002, 18: 91-95. (Chinese, English abstract)
34. Jiao B, Li C, Zhang Q, Bai B, Geng S. In vitro experiment research of the antiglioma activity of the glioma vaccine made from dendritic cell. Chin J Neurosurg Dis Res 2005, 4: 486-491.
35. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, et al. Vaccination of gliom a patients with fusions of dendritic and glioma cells and recombinant human interleukin-12. J Immunother 2004, 27: 452-459.
36. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999, 59: 3340-3345.
37. Ali S, Curtin JF, Zirger JM, Xiong W, King GD, Barcia C, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 2004, 10: 1071-1084.
38. + T-cell in humans without foreign helper epitopes. J Clin Invest 2000, 105: R9-R14.